An interventional study of Jianmin Daopeng Angong Niuhuang Wan and Tongrentang Angong Niuhuang Wan in Traumatic Brain Injury, sponsored by Huaqiu Zhang. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-07-20.
Sponsored by Huaqiu Zhang · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Brain Injuries, Traumatic with a site in China — 29 open to participants now, 30 under way, none of them phase 3. Brain Injuries, Traumatic · China.
Among the 60 studies in Brain Injuries, Traumatic with a site in China, this one is the 17th largest by planned enrollment of the 26 interventional ones that give a count, is one of 7 that started in 2025, is one of 18 with no phase, reaches primary completion later than 21 of the 29 other live ones, and was the 53rd registered.
1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.
Browse Brain Injuries, Traumatic studies →29 of the 60 studies in Brain Injuries, Traumatic with a site in China are open now. Recruiting first, the newest first:
Zhangjiagang First People's Hospital · Sites in China
Ages 18–65
Shanghai 6th People's Hospital · Sites in China
Ages 18–80 · Healthy volunteers
Tang-Du Hospital · Sites in China
Ages 18–75
Shanxi Bethune Hospital · Sites in China
Ages 18–75
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18–90
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 1 · Phase 4 3
First in 2006; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 52 across 1,091 interventional studies indexed under Brain Injuries, Traumatic.
Median enrollment 83 across the 26 interventional studies, 110 across the 34 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 60 has an industry lead sponsor. The 10 most frequent:
Huaqiu Zhang is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
Huaqiu Zhang has 1 study filed under Brain Injuries, Traumatic — fewer than ten, so there is no comparison to draw.
7 of the studies in Brain Injuries, Traumatic with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07115459Xiangya Hospital of Central South UniversityDevelopment and Validation of a Prognostic Model for Neurocritical Patients Using Multimodal Brain Monitoring | 2026-12-31 |
| NCT06429774Beijing Tiantan HospitalComparative Effectiveness of Intervention in Multi-level Hospitals for Acute Traumatic Brain Injury(Metric-TBI) | 2026-12-31 |
| NCT04900168Tang-Du HospitalIntracranial Pressure Monitoring in Moderate Traumatic Brain Injury | 2026-12-31 |
| NCT06241482Shanghai 6th People's HospitalSafety and Efficacy of Enhanced Recovery After Surgery in Neurocritical Care | 2027-04-30 |
| NCT06909071Shanxi Bethune HospitalHybrid Closed-Loop System in Neurosurgical Perioperative Hyperglycemia: An Open RCT | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 60 studies in Brain Injuries, Traumatic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Clinical Challenges and Severity of Traumatic Brain Injury: Traumatic brain injury, as a common neurosurgical disease, poses a significant threat to patients' life safety and quality of life.The promotion of in vitro cultivated cow bile in the treatment of post-traumatic brain injury is expected to provide a more economical and effective treatment option for the recovery of consciousness and cognitive functions of TBI patients. Compared with traditional An Gong Niu Huang Wan, Jian Min Da Peng's An Gong Niu Huang Wan (containing in vitro cultivated cow bile) can not only reduce treatment costs, but also improve the stability and consistency of the quality of the drug. The above clinical research can provide scientific basis for including it in relevant treatment guidelines.
Clinical Challenges and Severity of Traumatic Brain Injury: Traumatic brain injury, as a common neurosurgical disease, poses a significant threat to patients' life safety and quality of life. Post-operative patients with traumatic brain injury often suffer from severe neurological impairments, consciousness disorders, systemic inflammatory responses, and even pose a threat to their lives. The recovery of consciousness and cognitive functions is of great significance for patients' quality of life and functional rehabilitation.
Clinical Status: Currently, the treatment methods for traumatic brain injury include early emergency surgical treatment of the primary injury (such as surgical removal of intracranial hematoma, contusion and laceration of brain tissue, etc.) and post-operative drug and rehabilitation treatment for secondary neurological dysfunction (including but not limited to neurological function recovery, treatment of brain tissue edema, treatment of cerebral ischemia and its systemic inflammatory responses). For a long time, An Gong Niu Huang Wan has been used as a traditional Chinese medicine for some patients with clinical brain injury due to its significant pharmacological functions such as anti-inflammatory and clearing heat, awakening the mind and opening the orifices. However, due to the scarcity and high price of the active ingredient "natural cow bile" in An Gong Niu Huang Wan, its wide application in these patients has been limited. Jian Min Da Peng An Gong Niu Huang Wan is a kind of artificial cow bile synthesized and cultivated in the laboratory through in vitro cultivation, which has similar pharmacological properties to natural cow bile. It can not only effectively solve the problem of shortage of natural cow bile resources and high cost, but also has significant advantages in quality control.
Research Significance: The promotion of in vitro cultivated cow bile in the treatment of post-traumatic brain injury is expected to provide a more economical and effective treatment option for the recovery of consciousness and cognitive functions of TBI patients. Compared with traditional An Gong Niu Huang Wan, Jian Min Da Peng's An Gong Niu Huang Wan (containing in vitro cultivated cow bile) can not only reduce treatment costs, but also improve the stability and consistency of the quality of the drug. The above clinical research can provide scientific basis for including it in relevant treatment guidelines.
Shortcomings and Innovation Points of Existing Studies: Although An Gong Niu Huang Wan, as a traditional drug for promoting neurological function recovery, has achieved certain effects in some patients, there is a lack of standardized clinical research. The instability of treatment effects in different types of patients has led to the lack of wide recognition from clinical physicians. While in vitro cultivated cow bile is an emerging treatment method, it still lacks sufficient clinical research support. Therefore, this study fills this research gap by comparing the effect of the experimental group (Jian Min Da Peng An Gong Niu Huang Wan group) and the control group (Tong Ren Tang An Gong Niu Huang Wan group) on the recovery of neurological function in post-traumatic brain injury patients, which is highly innovative.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Jianmin Dapeng Angong Niuhuang Wan. All the enrolled patients were given oral medication. For those who were unable to eat independently, nasogastric administration was carried out using warm water to dissolve the medicine. Usage and dosage: Oral administration, 1 pill each time, once a day, for 1 week.
Drug: Jianmin Daopeng Angong Niuhuang Wan
Tongrentang Angong Niuhuang Wan. All the enrolled patients were given oral medication. For those who were unable to eat independently, nasogastric administration was carried out using warm water to dissolve the medicine. Usage and dosage: Oral administration, 1 pill each time, once a day, for 1 week.
Drug: Tongrentang Angong Niuhuang Wan
An Gong Niu Huang Wan comes from JianMin Dapeng.
Angong Niuhuang Wan comes from Tongrentang.
The changes in GCS scores before and after treatment 2 week
We compared the improvement effects of oral administration of Jianmin Dapeng An Gong Niu Huang Wan (containing in vitro cultivated rhinoceros horn) and Tong Ren Tang An Gong Niu Huang Wan (containing natural rhinoceros horn) on the recovery of neurological function in patients with brain trauma after surgery (calculation method: compare the changes in GCS before and after treatment of the two groups, the improvement effect of neurological function = final GCS test score - GCS test score before treatment)
Time frame: 2 week
The changes in GCS scores before and after treatment 1 week
We compared the improvement effects of oral administration of Jianmin Dapeng An Gong Niu Huang Wan (containing in vitro cultivated rhinoceros horn) and Tong Ren Tang An Gong Niu Huang Wan (containing natural rhinoceros horn) on the recovery of neurological function in patients with brain trauma after surgery (calculation method: compare the changes in GCS before and after treatment of the two groups, the improvement effect of neurological function = final GCS test score - GCS test score before treatment)
Time frame: 1 week
Inflammatory factors: the levels of Inflammatory factors(IL-2, IL-6, WBC, neutrophils, lymphocytes, monocytes, platelets)
The levels of inflammatory factors (IL-2, IL-6, WBC, neutrophils, lymphocytes, monocytes, platelets) in brain injury patients one week and two weeks after oral administration of Jianmin Dapeng An Gong Niu Huang Wan (containing in vitro cultivated ox bile) and Tong Ren Tang An Gong Niu Huang Wan (containing natural ox bile) for treatment were compared with those before treatment.
Time frame: 1 week and 2 week
Brain injury indicators: The levels of brain injury indicators (GFAP, NSE, S100-beta)
Brain injury indicators: The levels of brain injury indicators (GFAP, NSE, S100-beta) in patients with brain trauma after surgery, one week and two weeks after taking Jianmin Dapeng An Gong Niu Huang Pills (containing in vitro cultivated ox bile) and Tongrentang An Gong Niu Huang Pills (containing natural ox bile) were compared with those before treatment.
Time frame: 1 week and 2 week
Imaging assessment: MRI and CT
Imaging assessment: This includes MRI and CT. Observing the recovery of the restoration of normal neural tissue structure in patients with brain trauma after one week and two weeks of oral administration of Jianmin Daopeng Anjungniuhuang Wan (containing in vitro cultivated rhinoceros horn) and Tongrentang Anjungniuhuang Wan (containing natural rhinoceros horn) treatment.
Time frame: 1 week and 2 week
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Jul 2027, 24 months after the start.
Of 445 non-industry interventional studies with no phase under Brain Injuries, Traumatic, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's planned 24 months is below that.
Counting every sponsor, half of 467 studies reached it within 41 months; a quarter within 22 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Huaqiu Zhang